STAT2 anticorps (N-Term, pTyr690)

N° du produit ABIN401443

Détail du produit anti-STAT2 anticorps

Antigène: STAT2 (Signal Transducer and Activator of Transcription 2, 113kDa (STAT2))

Épitope: N-Term, pTyr690

Reactivité: Humain, Rat, Souris

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp STAT2 est non-conjugé

Application: Western Blotting (WB), Enzyme Immunoassay (EIA)

Specificité: This purified antibody is directed against STAT2 pY690 protein.

Réactivité croisée (Details): Species reactivity (expected):Rat, Mouse.
Species reactivity (tested):Human.

Purification: Affinity chromatography

Immunogène: Synthetic peptide corresponding to a region near the N-terminus of human STAT2 protein

Isotype: IgG

Information d'application

Indications d'application: ELISA: 1/85,000. Western Blot: 1/500 - 1/1000.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Restrictions: For Research Use only

Stockage

Concentration: 1.15 mg/mL (by UV absorbance at 280 nm)

Buffer: 0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2 containing 0.01 % (w/v) Sodium Azide

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Avoid repeated freezing and thawing.

Stock: -20 °C

Détails sur STAT2

Antigène: STAT2 (Signal Transducer and Activator of Transcription 2, 113kDa (STAT2))

Autre désignation: STAT2 (STAT2 Produits)

Synonymes: anticorps wu:fj84d07, anticorps p113, anticorps stat2, anticorps 1600010G07Rik, anticorps AW496480, anticorps ISGF-3, anticorps P113, anticorps STAT113, anticorps signal transducer and activator of transcription 2, anticorps AGAP000099-PA, anticorps stat2, anticorps STAT2, anticorps Stat2

Sujet: STAT2 is a member of the STAT family of transcription factors. Unlike other STATs, STAT2 is unique as it can only be activated by interferons (IFNs). STAT2 is a critical component in mediating many IFN-stimulated biological activities including antiproliferation and antiviral responses. Upon IFN treatment, STAT1 and STAT2 become tyrosine phosphorylated, assemble as heterodimers that bind IRF9 to form the ISGF3 complex. This complex translocates to the nucleus, binds to promoters of IFN-stimulated genes and mediates gene transcription. Consequently, mutations in STAT2 or loss of STAT2 expression leads to impairment in IFN signal transduction and gene activation. IFN-alpha is an approved drug for the treatment of several forms of cancer. Yet only a subset of patients who receive IFN-alpha therapy benefit from the treatment. Given that STAT2 is activated by IFNs, it is important to define if the reduced or lack of antitumor effects seen in cancer patients on IFN therapy is due to in defects in STAT2 function. Our goal is to identify regions/motifs within the structural domains of STAT2 that not only are essential for the tyrosine phosphorylation of STAT2, but also regulate the antitumor effects of IFN-alpha. Collectively, the results of our studies will emphasize the physiological role of STAT2 in cancer. From a clinical viewpoint, cancer patients who may benefit the most from receiving IFN-alpha therapy can be selected based on their STAT2 function.Synonyms: Signal transducer and activator of transcription 2, p113

ID gène: 6773

NCBI Accession: NP_005410

UniProt: P52630

Pathways: Signalistation JAK/STAT, Hepatitis C, CXCR4-mediated Signaling Events